IFNA1 and systemic lupus erythematosus: After the “Treatment of Uncontrolled Lupus via the IFN Pathway” (TULIP) 2 trial, it was approved for SLE by the FDA in 2021 [241], whereas TULIP LN assessed its use as an induction therapy for LN (in addition to MMF and steroid) in 2022 [222].